Virtual Chromoendoscopy: Is This the Future of Colitis Surveillance?
"A randomized trial reveals virtual chromoendoscopy as a quicker, more comfortable alternative for detecting dysplasia in colitis patients, potentially improving adherence to crucial surveillance programs."
For individuals with ulcerative colitis (UC) or colonic Crohn's disease (CD), the risk of colorectal cancer (CRC) is a significant concern, making regular surveillance colonoscopies a critical part of their healthcare. Traditional chromoendoscopy (CE) is a recommended surveillance method, but its widespread adoption has been limited.
Virtual chromoendoscopy (VCE) offers a promising alternative. By digitally enhancing mucosal images in real-time, VCE eliminates the technical challenges associated with traditional CE. Fujinon Intelligent Colour Enhancement (FICE), a specific VCE technology, has shown promise in detecting adenomas in non-colitis studies.
A recent study, the 'CONVINCE' trial, directly compared VCE to conventional CE, focusing on dysplasia detection, feasibility, and, importantly, patient experience. This research provides crucial insights into whether VCE could overcome the barriers to colitis surveillance and improve patient outcomes.
Why Colitis Surveillance Matters
Longstanding colonic inflammatory bowel disease (IBD) is associated with increased colorectal cancer risk. Chromoendoscopy using standard-definition white-light technology has an established role, while the performance of high-definition virtual chromoendoscopy (HDV) in colitis surveillance was described as undefined in the 2020 trial report. A prospective randomized trial also compared dye-based chromoendoscopy with i-scan virtual chromoendoscopy for detecting neoplasia in people with long-standing ulcerative colitis.
How Surveillance Guidance Took Shape
A 2022 review describes its literature search using terms including “surveillance,” “dye chromoendoscopy,” “virtual chromoendoscopy,” and “endocytoscopy,” alongside terms for dysplasia and IBD. A feasibility-study summary says colitis surveillance is needed because cancer-associated dysplasia can appear as flat lesions that routine colonoscopy may miss, and reports that NICE guidelines recommend chromoendoscopy. Another study listing states that patients with longstanding ulcerative colitis extending beyond the rectum should enter surveillance eight years after diagnosis.
CONVINCE Trial: VCE vs. Conventional Chromoendoscopy
The CONVINCE trial was designed as a randomized crossover study. This means participants underwent both VCE and conventional CE, allowing for a direct comparison of the two techniques within the same individuals. Researchers evaluated several factors, including the ability to detect dysplasia (precancerous changes), the time taken for each procedure, patient-reported pain levels, and overall patient preference.
- Dysplasia Detection: VCE's dysplasia diagnostic accuracy was 93.94%, compared to 76.9% for conventional CE. VCE didn't miss more dysplasia.
- Examination Time: VCE was significantly faster, averaging 14 minutes compared to 20 minutes for CE (p < 0.001).
- Pain Levels: Patients reported lower pain scores with VCE (27.4 mm on a visual analog scale) compared to CE (34.7 mm).
- Patient Preference: A clear majority (67%) of patients preferred VCE, while only 33% preferred conventional CE (p < 0.001).
Recent Trials and Evidence Reviews
A prospective single-center randomized study enrolled 300 adults with ulcerative colitis or Crohn’s colitis undergoing surveillance colonoscopy, randomizing 150 to methylene-blue dye-based chromoendoscopy and 150 to Fujifilm blue-light imaging or linked-color imaging. A systematic review covering eight studies and 985 patients reported that virtual chromoendoscopy had dysplasia-detection ability similar to dye-based chromoendoscopy, with shorter examination times. A separate study describes surveillance colonoscopy programs in IBD as associated with reduced colorectal cancer incidence.
Comparing Dye and Virtual Techniques
Dye-based chromoendoscopy is recommended for dysplasia surveillance in IBD, while virtual chromoendoscopy systems are increasingly used as practical alternatives. The 2026 study description notes that prospective direct comparisons on a single imaging platform remain limited. It sets out to compare dysplasia detection using methylene-blue dye-based chromoendoscopy, with the corresponding PubMed record reporting the same comparison focus.
The Future of Colitis Surveillance: VCE's Potential
The CONVINCE trial offers compelling evidence that virtual chromoendoscopy could be a valuable tool in colitis surveillance. Its ease of use, speed, and improved patient experience could lead to greater adherence to surveillance programs, ultimately improving outcomes for individuals at risk of colorectal cancer.
Where Virtual Chromoendoscopy May Go Next
A 2022 review says it remains unclear whether dye chromoendoscopy, virtual chromoendoscopy, or white-light endoscopy is more efficient when high-definition scopes are used. It discusses present and future perspectives for i-scan virtual chromoendoscopy and the advent of optical-enhancement technology. A 2025 summary describes a Netherlands randomized trial comparing three approaches in people with IBD without active inflammation: high-definition white-light endoscopy with segmental reinspection, single-pass high-definition white-light endoscopy, and high-definition chromoendoscopy.
Surveillance in Community Practice
A real-life study evaluated chromoendoscopy for ulcerative-colitis surveillance in a community-hospital setting. It focused on patients with extensive ulcerative colitis lasting more than eight years who presented during the study period. The source frames the work as an assessment of how chromoendoscopy is used in routine community practice.
While these results are promising, the researchers emphasize that this was a feasibility trial. A larger, multicenter trial is needed to confirm these findings and further establish the value of VCE in clinical practice. This future research will provide more definitive evidence to guide clinical recommendations.
In the meantime, patients with colitis should discuss the available surveillance options with their gastroenterologist. VCE represents a step forward in making this critical aspect of healthcare more accessible and patient-centered.